Giandomenico Maggiore
Overview
Explore the profile of Giandomenico Maggiore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vivarelli E, Perlato M, Accinno M, Brugnoli B, Milanese M, Cataudella E, et al.
Respiration
. 2025 Mar;
:1-15.
PMID: 40064152
Introduction: Asthma is a heterogeneous chronic inflammatory disease involving different underling pathogenetic mechanisms. We aimed to investigate the characteristics of patients with the diagnosis of asthma and primary antibody immunodeficiency...
2.
Minzoni A, Orlando P, Maggiore G
Laryngoscope
. 2024 Nov;
134(12):E38.
PMID: 39540571
No abstract available.
3.
Orlando P, Vivarelli E, Minzoni A, Licci G, Accinno M, Brugnoli B, et al.
Eur Arch Otorhinolaryngol
. 2024 Oct;
282(1):265-272.
PMID: 39404884
Purpose: Mepolizumab was recently approved for treating Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) unresponsive to standard treatment or recurring after endoscopic sinus surgery (ESS). To date, few studies have assessed...
4.
Minzoni A, Mazzetti L, Orlando P, Licci G, Taccetti G, Bresci S, et al.
Eur Arch Otorhinolaryngol
. 2024 Aug;
281(12):6397-6404.
PMID: 39112557
Background: Chronic rhinosinusitis (CRS) is prevalent in cystic fibrosis (CF), significantly affecting quality of life. The introduction of CFTR modulators, including elexacaftor-tezacaftor-ivacaftor (ETI), offers promise for improving sinonasal outcomes. Methods:...
5.
Reale M, Licci G, Orlando P, Matucci A, Trabalzini F, Maggiore G, et al.
Eur Arch Otorhinolaryngol
. 2024 May;
281(10):5023-5031.
PMID: 38762844
Introduction: The recent approval of Dupilumab has profoundly revolutionized the management of patients affected by severe and recalcitrant Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). However, a review that summarizes the...
6.
Bagnasco D, Brussino L, Biagini C, Cosmi L, De Corso E, La Mantia I, et al.
World Allergy Organ J
. 2024 Apr;
17(4):100895.
PMID: 38590723
No abstract available.
7.
Orlando P, Licci G, Kuitche D, Matucci A, Vultaggio A, Gallo O, et al.
Eur Arch Otorhinolaryngol
. 2023 Nov;
281(3):1317-1324.
PMID: 37910208
Purpose: Historically managed with intranasal corticosteroids (INCS) and endoscopic sinus surgery (ESS), type-2 Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) treatment was revolutionized by the introduction of dupilumab but universally accepted...
8.
Canevari F, Giorli A, Monti G, Biagini C, Bagnasco D, Cavaliere C, et al.
Front Allergy
. 2023 Oct;
4:1237131.
PMID: 37841050
Chronic rhinosinusitis (CRS) is a complex and heterogeneous disorder whose etiopathogenetic picture is not yet completely known and is classically divided into CRS with (CRSwNP) and without nasal polyps (CRSsNP)....
9.
Vultaggio A, Accinno M, Vivarelli E, Mecheri V, Maggiore G, Cosmi L, et al.
Allergy
. 2023 Oct;
78(12):3154-3165.
PMID: 37792721
Background: Eosinophils have been divided into different subpopulations with distinct phenotypes based on CD62L expression. No data are available regarding the correlation between eosinophils subphenotypes and clinical severity of asthma,...
10.
Arcovito G, Caporalini C, Palomba A, Maggiore G, Franchi A
Oral Surg Oral Med Oral Pathol Oral Radiol
. 2023 Sep;
136(5):e153-e158.
PMID: 37735002
Nodular fasciitis (NF) is a benign myofibroblastic proliferation characterized by rapid growth, a self-limiting course, and USP6 gene rearrangement. Although it can arise in the head and neck region, very...